Resource Summary Report

Generated by nidm-terms on Aug 11, 2026

Brilliant Violet 421(TM) anti-human CD8

RRID:AB_2629583
Type: Antibody

Proper Citation

BioLegend Cat# 344747, RRID:AB_2629583

Antibody Information

URL: http://antibodyregistry.org/AB_2629583

Proper Citation: BioLegend Cat# 344747, RRID:AB_2629583

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2629583

Vendor: BioLegend

Catalog Number: 344747

Alternative Catalog Numbers: 344748

Record Creation Time: 20250820T045238+0000

Record Last Update: 20250820T201035+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD8.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

He C, et al. (2026) RNF138 promotes cisplatin resistance and PD-L1-mediated immune evasion via JAK2/STAT3 activation in nasopharyngeal carcinoma. Cell reports, 45(6), 117547.

Cheng BY, et al. (2026) Pharmacologic glycoengineering of Fc? receptor IIIa enhances force-resistant IgG-Fc?R interactions and anti-tumor antibody efficacy. Immunity, 59(7), 2030.

Shane J, et al. (2026) Genetically engineered eye-colonizing microbes that deliver the anti-inflammatory cytokine interleukin-10 enhance corneal tissue repair. Cell reports, 45(3), 117064.

Wei Y, et al. (2025) Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. Immunity.

Hodel AW, et al. (2025) Acidic pH can attenuate immune killing through inactivation of perforin. EMBO reports, 26(4), 929.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. Clinical and experimental immunology.

Jacob-Dolan C, et al. (2024) B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S. iScience, 27(5), 109716.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. Cell reports, 43(2), 113767.

Gravina A, et al. (2023) Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity. Cell stem cell, 30(11), 1538.

Xiong H, et al. (2023) Cytotoxic CD161-CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus. EBioMedicine, 90, 104507.

Siemionow M, et al. (2023) Novel Human Umbilical Di-Chimeric (HUDC) cell therapy for transplantation without life-long immunosuppression. Stem cell investigation, 10, 16.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Wenes M, et al. (2022) The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function. Cell metabolism, 34(5), 731.

Derada Troletti C, et al. (2021) Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome. Cell reports, 35(9), 109201.